Buy rating. MasterCard ( MA ) estimates, target raised at UBS. Shares are now seen reaching $457. Estimates were also increased as share wins add momentum, UBS said. Neutral rating. Onyx Pharmaceuticals ( ONXX ) was cut from the Conviction Buy List at Goldman Sachs. Valuation call, based on a $52 price target, Goldman said. Onyx Pharmaceuticals numbers were increased at Morgan Stanley. Estimates were raised through 2014. Company is expanding margins, Morgan Stanley said. Underweight rating and new $39 price target. Och-Ziff Capital Management ( OZM ) numbers were lowered at Citigroup. Shares are now seen reaching $11.50. Estimates were also lowered to reflect higher share count and slightly lower AUM compounding, Citi said. Buy rating. Petsmart ( PETM ) estimates, price target were increased at Bank of America/Merrill Lynch. Industry trends have are encouraging, BofA/Merrill said.